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Please note: 
Within this document you find general information about the drug of interest and the indication it is 
intended to be used for. Further we have included full text publications and conference abstracts of 
phase III trials, assessing the safety and efficacy of the drugs of interest. 
At the very end of each chapter we have provided a table containing the prioritization criteria and a 
drop-down field to apply the provided criteria. 
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Introduction 
As part of the project „Horizon Scanning in Oncology“ (further information can be found here: 
http://hta.lbg.ac.at/page/horizon-scanning-in-der-onkologie), 9 information sources are scanned 
frequently to identify emerging anticancer drugs. 
Every 3 months, these anticancer therapies are filtered (i.e. in most cases defined as availability of 
phase III results; for orphan drugs also phase II) to identify drugs at/around the same time as the 
accompanying drug licensing decisions of the EMA.  
An expert panel consisting of oncologists and pharmacists then applies 5 prioritisation criteria to 
elicit those anti-cancer therapies which might be associated with either a considerable impact on 
financial resources or a substantial health benefit.  
For the 35
th
 prioritisation (March 2018), eight drugs were filtered out of 404 identified and were sent 
to prioritisation. Of these, six drugs were ranked as ‘highly relevant’ by the expert panel, one as 
‘relevant’ and one as ‘not relevant’. For ‘highly relevant’ drugs, further information including, for 
example, abstracts of phase III studies and licensing status is contained in this document. 
The summary judgements of the expert panel for all prioritised drugs are provided in the following 
table. 
 
No Filtered Drugs – 35th prioritisation 2nd quarter 2018 Overall category 
1. 
Acalabrutinib (Calquence
®
) in relapsed or refractory mantle 
cell lymphoma (MCL) Relevant 
2. 
Apalutamide (Erleada
®
) treatment and metastasis-free 
survival in prostate cancer Highly relevant 
3. 
Buparlisib plus fulvestrant in postmenopausal women with 
hormone-receptor-positive, HER2-negative, advanced 
breast cancer progressing on or after mTOR inhibition 
Not relevant 
4. 
Dual human epidermal growth factor receptor 2 (HER2) 
blockade with lapatinib (Tyverb
®
) plus trastuzumab in 
combination with an aromatase inhibitor in postmenopausal 
women with HER2-positive, hormone receptor-positive 
metastatic breast cancer 
Highly relevant 
5. 
Daratumumab (Darzalex
®
) plus bortezomib, melphalan, and 
prednisone for untreated myeloma Highly relevant 
6. 
Dacomitinib versus gefitinib as first-line treatment for 
patients with EGFR-mutation-positive non-small-cell lung 
cancer (NSCLC) 
Highly relevant 
7. 
Osimertinib (Tagrisso
®
) in untreated EGFR-mutated 
advanced NSCLC Highly relevant 
8. 
Rucaparib (Rubraca
®
) maintenance treatment for recurrent 
ovarian carcinoma after response to platinum therapy  Highly relevant 
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1 Prostate Cancer 
1.1 Apalutamide (Erleada®) treatment and metastasis-free survival 
in prostate cancer 
Overview 
Drug Description a competitive inhibitor of the androgen receptor 
Patient Indication 
patients with nonmetastatic castration-resistant prostate cancer who are at 
high risk for the development of metastasis 
Incidence in 
Austria 
4,854 newly diagnosed per year (2015), 130.6/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III 
NCT02489318 until July 2022 
NCT02257736 until August 2021 
Approval 
status for 
this 
indication 
EMA - 
FDA 
02/2018: the FDA approved apalutamide for patients with non-metastatic 
castration-resistant prostate cancer  
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
 
Phase III results  
NEJM; available online February 8, 2018 (Smith et al.): “Apalutamide treatment and metastasis-free 
survival in prostate cancer”   
 
Background 
Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment 
of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-
resistant prostate cancer who were at high risk for the development of metastasis. 
Methods 
We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic 
castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. 
Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. 
All the patients continued to receive androgen-deprivation therapy. The primary end point was 
metastasis-free survival, which was defined as the time from randomization to the first detection of 
distant metastasis on imaging or death. 
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Results 
A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo 
group). In the planned primary analysis, which was performed after 378 events had occurred, median 
metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in 
the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 
0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with 
placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to 
discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo 
group. The following adverse events occurred at a higher rate with apalutamide than with placebo: 
rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%). 
Conclusion 
Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time 
to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by 
Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204.) 
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2 Breast Cancer 
2.1 Dual human epidermal growth factor receptor 2 (HER2) 
blockade with lapatinib (Tyverb®) plus trastuzumab in 
combination with an aromatase inhibitor in postmenopausal 
women with HER2-positive, hormone receptor-positive 
metastatic breast cancer 
Overview 
Drug Description 
small molecule dual inhibitor of HER1 (ErbB1) and HER2 (ErbB2) receptor 
tyrosine kinases  
Patient Indication 
postmenopausal women with HER2-positive/HR-positive metastatic breast 
cancer who received prior endocrine therapy and prior neo(adjuvant)/first-
line trastuzumab plus chemotherapy. 
Incidence in 
Austria 
5,390 newly diagnosed per year (2015), 63.3/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT00667251 until December 2020 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
06/2008: lapatinib (LAP) in combination with capecitabine for the treatment 
of patients with advanced or metastatic breast cancer whose tumours 
overexpress ErbB2 (HER2) and who have received prior therapy including 
trastuzumab (TRAS) 
02/2010: for the treatment of patients with breast cancer, whose tumours 
overexpress HER2 (ErbB2); in combination with an aromatase inhibitor 
(AI) for postmenopausal women with hormone receptor positive metastatic 
disease, not currently intended for chemotherapy. The patients in the 
registration study were not previously treated with trastuzumab or an 
aromatase inhibitor 
06/2013: indicated for the treatment of adult patients with breast cancer, 
whose tumours overexpress HER2 (ErbB2); in combination with 
trastuzumab  for patients with hormone receptor-negative metastatic 
disease that has progressed on prior trastuzumab therapy(ies) in 
combination with chemotherapy  
FDA 
03/2007: in combination with capecitabine, for the treatment of patients 
with advanced or metastatic breast cancer whose tumors overexpress 
HER2 and who have received prior therapy including an anthracycline, a 
taxane, and trastuzumab 
01/2010: in combination with letrozole for the treatment of postmenopausal 
women with hormone-receptor positive metastatic breast cancer that 
overexpresses the HER2 receptor for whom hormonal therapy is indicated 
Costs 
1 treatment cycle (21 days): oral 1,000 mg/day (LAP+TRAS+AI arm) or 
1,500 mg/day (LAP+AI arm);  
ex-factory price: 84 Tyverb
®
 tablets a 250 mg € 1,481.70 ->  
costs for 1 treatment cycle of lapatinib in the LAP+TRAS+AI arm: € 
1,481.70 or 
ex-factory price: 70 Tyverb
®
 tablets a 250 mg € 1235.07 -> costs for 
treatment cycle of lapatinib in the LAP+AI arm: € 2,470.14 
Additional costs will incur due to the combination treatment of LAP with 
TRAS and and AI (letrozole, anastrozole or exemestane) 
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Phase III results  
Journal of Clinical Oncology; available online December 15, 2017 (Johnston et al.): “Phase III, 
randomized study of dual human epidermal growth factor receptor 2 (HER2) blockade with lapatinib 
plus trastuzumab in combination with an aromatase inhibitor in postmenopausal women with HER2-
positive, hormone receptor–positive metastatic breast cancer: ALTERNATIVE” 
Background  
Human epidermal growth factor receptor 2 (HER2) targeting plus endocrine therapy (ET) improved 
clinical benefit in HER2-positive, hormone receptor (HR)–positive metastatic breast cancer (MBC) 
versus ET alone. Dual HER2 blockade enhances clinical benefit versus single HER2 blockade. The 
ALTERNATIVE study evaluated the efficacy and safety of dual HER2 blockade plus aromatase 
inhibitor (AI) in postmenopausal women with HER2-positive/HR-positive MBC who received prior ET 
and prior neo(adjuvant)/first-line trastuzumab (TRAS) plus chemotherapy. 
 
Methods  
Patients were randomly assigned (1:1:1) to receive lapatinib (LAP) + TRAS + AI, TRAS + AI, or LAP + 
AI. Patients for whom chemotherapy was intended were excluded. The primary end point was 
progression-free survival (PFS; investigator assessed) with LAP + TRAS + AI versus TRAS + AI. 
Secondary end points were PFS (comparison of other arms), overall survival, overall response rate, 
clinical benefit rate, and safety. 
 
Results 
Three hundred fifty-five patients were included in this analysis: LAP + TRAS + AI (n = 120), TRAS + AI 
(n = 117), and LAP + AI (n = 118). Baseline characteristics were balanced. The study met its primary 
end point; superior PFS was observed with LAP + TRAS + AI versus TRAS + AI (median PFS, 11 v 
5.7 months; hazard ratio, 0.62; 95% CI, 0.45 to 0.88; P = .0064). Consistent PFS benefit was 
observed in predefined subgroups. Overall response rate, clinical benefit rate, and overall survival also 
favored LAP + TRAS + AI. The median PFS with LAP + AI versus TRAS + AI was 8.3 versus 5.7 
months (hazard ratio, 0.71; 95% CI, 0.51 to 0.98; P = .0361). Common adverse events (AEs; ≥15%) 
with LAP + TRAS + AI, TRAS + AI, and LAP + AI were diarrhea (69%, 9%, and 51%, respectively), 
rash (36%, 2%, and 28%, respectively), nausea (22%, 9%, and 22%, respectively), and paronychia 
(30%, 0%, and 15%, respectively),mostly grade 1 or 2. Serious AEs were reported similarly across the 
three groups, and AEs leading to discontinuation were lower with LAP + TRAS + AI. 
 
Interpretation  
Dual HER2 blockade with LAP + TRAS + AI showed superior PFS benefit versus TRAS + AI in 
patients with HER2-positive/HR-positive MBC. This combination offers an effective and safe 
chemotherapy-sparing alternative treatment regimen for this patient population. 
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3 Multiple Myeloma 
3.1 Daratumumab (Darzalex®) plus bortezomib, melphalan, and 
prednisone for untreated myeloma 
Overview 
Drug Description 
human CD38-directed monoclonal antibody (CD38 is a transmembrane 
glycoprotein (48kDa) expressed on the surface of haematopoietic cells 
Patient Indication 
in combination with bortezomib, melphalan and prednisone for patients 
with newly diagnosed multiple myeloma who are ineligible for autologous 
stem-cell transplantation 
Incidence in 
Austria 
409 newly diagnosed per year (2015), 4.9/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III 
NCT02252172 until November 2024 
NCT03217812 until October 2022 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
07/2013: orphan designation was granted for daratumumab for the 
treatment of plasma-cell myeloma 
 
05/2016: as monotherapy for the treatment of adult patients with relapsed 
and refractory multiple myeloma, whose prior therapy included a 
proteasome inhibitor and an immunomodulatory agent and who have 
demonstrated disease progression on the last therapy 
 
02/2017: in combination with lenalidomide and dexamethasone, or 
bortezomib and dexamethasone, for the treatment of adult patients with 
multiple myeloma who have received at least one prior therapy 
 
FDA 
11/2015 (accelerated approval): indicated for the treatment of patients with 
multiple myeloma who have received at least three prior lines of therapy 
including a proteasome inhibitor (PI) and an immunomodulatory agent or 
who are double-refractory to a PI and an immunomodulatory agent 
11/2016: in combination with lenalidomide and dexamethasone, or 
bortezomib and dexamethasone, for the treatment of patients with multiple 
myeloma who have received at least one prior therapy  
06/2017: in combination with pomalidomide and dexamethasone for the 
treatment of patients with multiple myeloma who have received at least 
two prior therapies including lenalidomide and a proteasome inhibitor  
Costs 
Daratumumab (1 cycle = 42 days):  
Cycle 1: IV 16 mg/kg/once weekly, assuming an average body weight of 
70 kg, 1,120 mg/week are needed. One vial of concentrate for solution for 
infusion containing 400 mg costs € 2,096.0 (ex-factory price) -> 
€6,288.0/week x6 = € 37,728 for the first cycle 
Cycle 2-9: daratumumab is administered every 3 weeks, costs for one 
cycle: € 12,576.0 
Subsequent cycles: daratumumab is administered every 4 weeks, costs 
for one cycle: € 9,432.0 
Additionally, costs for bortezomib, melphalan, and prednisone incur; in the 
experimental group dexamethasone was added as well to manage 
infusion reactions 
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Phase III results  
NEJM; available online December 12, 2017 (Mateos et al.): “Daratumumab plus bortezomib, 
melphalan, and prednisone for untreated myeloma” 
 
Background  
The combination of bortezomib, melphalan, and prednisone is a standard treatment for patients with 
newly diagnosed multiple myeloma who are ineligible for autologous stem-cell transplantation. 
Daratumumab has shown efficacy in combination with standard-of-care regimens in patients with 
relapsed or refractory multiple myeloma. 
 
Methods  
In this phase 3 trial, we randomly assigned 706 patients with newly diagnosed multiple myeloma who 
were ineligible for stem-cell transplantation to receive nine cycles of bortezomib, melphalan, and 
prednisone either alone (control group) or with daratumumab (daratumumab group) until disease 
progression. The primary end point was progression-free survival. 
 
Findings  
At a median follow-up of 16.5 months in a prespecified interim analysis, the 18-month progression-free 
survival rate was 71.6% (95% confidence interval [CI], 65.5 to 76.8) in the daratumumab group and 
50.2% (95% CI, 43.2 to 56.7) in the control group (hazard ratio for disease progression or death, 0.50; 
95% CI, 0.38 to 0.65; P<0.001). The overall response rate was 90.9% in the daratumumab group, as 
compared with 73.9% in the control group (P<0.001), and the rate of complete response or better 
(including stringent complete response) was 42.6%, versus 24.4% (P<0.001). In the daratumumab 
group, 22.3% of the patients were negative for minimal residual disease (at a threshold of 1 tumor cell 
per 105 white cells), as compared with 6.2% of those in the control group (P<0.001). The most 
common adverse events of grade 3 or 4 were hematologic: neutropenia (in 39.9% of the patients in 
the daratumumab group and in 38.7% of those in the control group), thrombocytopenia (in 34.4% and 
37.6%, respectively), and anemia (in 15.9% and 19.8%, respectively). The rate of grade 3 or 4 
infections was 23.1% in the daratumumab group and 14.7% in the control group; the rate of treatment 
discontinuation due to infections was 0.9% and 1.4%, respectively. Daratumumab-associated infusion-
related reactions occurred in 27.7% of the patients. 
 
Interpretation  
Among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell 
transplantation, daratumumab combined with bortezomib, melphalan, and prednisone resulted in a 
lower risk of disease progression or death than the same regimen without daratumumab. The 
daratumumab-containing regimen was associated with more grade 3 or 4 infections. (Funded by 
Janssen Research and Development; ALCYONE ClinicalTrials.gov number, NCT02195479.) 
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4 Lung Cancer 
4.1 Dacomitinib versus gefitinib as first-line treatment for patients 
with EGFR-mutation-positive non-small-cell lung cancer 
(NSCLC) 
Overview 
Drug Description a second-generation, irreversible EGFR tyrosine kinase inhibitor 
Patient Indication 
first-line treatment of patients with advanced EGFR-mutation-positive non-
small-cell lung cancer (NSCLC) 
Incidence in 
Austria 
4,860 newly diagnosed per year (2015), 57.9/100,000/year (European 
Standard Population, 2013), including lung, trachea and bronchial tumours 
Ongoing Phase III - 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
 
Phase III results  
Lancet (2017); 18: 1454–66; available online September 2017 (Wu et al.): “Dacomitinib versus 
gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer 
(ARCHER 1050): a randomised, open-label, phase 3 trial” 
 
Background  
Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor. We compared its 
efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor gefitinib in the first-line 
treatment of patients with advanced EGFR-mutation-positive non-small-cell lung cancer (NSCLC)
  
Methods  
In this international, multicentre, randomised, open-label, phase 3 study (ARCHER 1050), we enrolled 
adults (aged ≥18 years or ≥20 years in Japan and South Korea) with newly diagnosed advanced 
NSCLC and one EGFR mutation (exon 19 deletion or Leu858Arg) at 71 academic medical centres and 
university hospitals in seven countries or special administrative regions. We randomly assigned 
participants (1:1) to receive oral dacomitinib 45 mg/day (in 28-day cycles) or oral gefitinib 250 mg/day 
(in 28-day cycles) until disease progression or another discontinuation criterion was met. 
Randomisation, stratified by race and EGFR mutation type, was done with a computer-generated 
random code assigned by a central interactive web response system. The primary endpoint was 
progression-free survival assessed by masked independent review in the intention-to-treat population. 
Safety was assessed in all patients who received at least one dose of study treatment. This study is 
registered with ClinicalTrials.gov, number NCT01774721, and is ongoing but no longer recruiting 
patients. 
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Findings  
Between May 9, 2013, and March 20, 2015, 452 eligible patients were randomly assigned to receive 
dacomitinib (n=227) or gefitinib (n=225). Median duration of follow-up for progression-free survival was 
22.1 months (95% CI 20.3–23.9). Median progression-free survival according to masked independent 
review was 14.7 months (95% CI 11.1–16.6) in the dacomitinib group and 9.2 months (9.1–11.0) in the 
gefitinib group (hazard ratio 0.59, 95% CI 0.47–0.74; p<0.0001). The most common grade 3–4 
adverse events were dermatitis acneiform (31 [14%] of 227 patients given dacomitinib vs. none of 224 
patients given gefitinib), diarrhoea (19 [8%] vs. two [1%]), and raised alanine aminotransferase levels 
(two [1%] vs. 19 [8%]). Treatment-related serious adverse events were reported in 21 (9%) patients 
given dacomitinib and in ten (4%) patients given gefitinib. Two treatment-related deaths occurred in 
the dacomitinib group (one related to untreated diarrhoea and one to untreated cholelithases/liver 
disease) and one in the gefitinib group (related to sigmoid colon diverticulitis/rupture complicated by 
pneumonia). 
 
Interpretation  
Dacomitinib significantly improved progression-free survival over gefitinib in first-line treatment of 
patients with EGFR-mutation-positive NSCLC and should be considered as a new treatment option for 
this population. 
 
4.2 Osimertinib (Tagrisso®) in untreated EGFR-mutated advanced 
NSCLC 
Overview 
Drug Description 
irreversible epidermal growth factor receptor tyrosine kinase inhibitor 
(EGFR-TKI) that selectively inhibits both EGFR-TKI–sensitizing and EGFR 
T790M resistance mutations 
Patient Indication 
patients with previously untreated, EGFR mutation–positive 
advanced NSCLC 
Incidence in 
Austria 
4,860 newly diagnosed per year (2015), 57.9/100,000/year (European 
Standard Population, 2013), including lung, trachea and bronchial tumours 
Ongoing Phase III NCT02296125 until 06/2019 
Approval 
status for 
this 
indication 
EMA - 
FDA - 
Approval 
status for 
other 
indications 
EMA 
02/2016: for the treatment of adult patients with locally advanced or 
metastatic EGFR T790M mutation-positive NSCLC 
FDA 
11/2015 (accelerated approval): for the treatment of patients with 
metastatic EGFR T790M mutation-positive NSCLC (as detected by an 
FDA-approved test), who have progressed on or after EGFR TKI therapy 
Costs 
Osimertinib dose: 80 mg/day 
30 Tagrisso
®
 tablets a 80 mg costing € 6,132.50 (ex-factory price) 
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Phase III results  
NEJM; available online November 18, 2017 (Soria et al.): “Osimertinib in untreated EGFR-mutated 
advanced non–small-cell lung cancer” 
Background  
Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI– sensitizing and EGFR T790M resistance 
mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, 
EGFR mutation–positive advanced non–small-cell lung cancer (NSCLC). 
 
Methods  
In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR 
mutation–positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either 
osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg 
once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-
assessed progression-free survival. 
Findings  
The median progression-free survival was significantly longer with osimertinib than with standard 
EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% 
confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two 
groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 
1.90; P = 0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with 
osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival 
were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% 
CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for 
death, 0.63; 95% CI, 0.45 to 0.88; P = 0.007 [nonsignificant in the interim analysis]). Adverse events of 
grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%). 
 
Interpretation  
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR 
mutation–positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse 
events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125.) 
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5 Ovarian cancer 
5.1 Rucarparib (Rubraca®) maintenance treatment for recurrent 
ovarian carcinoma after response to platinum therapy 
Overview 
Drug Description a poly(ADP-ribose) polymerase inhibitor 
Patient Indication 
patients with a platinum-sensitive, high-grade serous or endometrioid 
ovarian, primary peritoneal, or fallopian tube carcinoma who received at 
least two previous platinum-based chemotherapy regimens 
Incidence in 
Austria 
659 newly diagnosed per year (2015), 14.1/100,000/year (European 
Standard Population, 2013) 
Ongoing Phase III NCT02855944 until June 2024 
Approval 
status for 
this 
indication 
EMA 
10/2012: orphan designation was granted for the treatment of ovarian 
cancer 
FDA 
12/2016 (accelerated approval): as monotherapy for the treatment of 
patients with deleterious BRCA mutation (germline and/or somatic) 
associated advanced ovarian cancer who have been treated with two or 
more chemotherapies 
Approval 
status for 
other 
indications 
EMA - 
FDA - 
Costs - 
 
Phase III results 
Lancet; available online September 12, 2017 (Coleman et al.): “Rucaparib maintenance treatment 
for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-
blind, placebo-controlled, phase 3 trial” 
Background  
Rucaparib, a poly(ADP-ribose) polymerase inhibitor, has anticancer activity in recurrent ovarian 
carcinoma harbouring a BRCA mutation or high percentage of genome-wide loss of heterozygosity. In 
this trial we assessed rucaparib versus placebo after response to second-line or later platinum-based 
chemotherapy in patients with high-grade, recurrent, platinum-sensitive ovarian carcinoma. 
 
Methods  
In this randomised, double-blind, placebo-controlled, phase 3 trial, we recruited patients from 87 
hospitals and cancer centres across 11 countries. Eligible patients were aged 18 years or older, had a 
platinum-sensitive, highgrade serous or endometrioid ovarian, primary peritoneal, or fallopian tube 
carcinoma, had received at least two previous platinum-based chemotherapy regimens, had achieved 
complete or partial response to their last platinum-based regimen, had a cancer antigen 125 
concentration of less than the upper limit of normal, had a performance status of 0–1, and had 
adequate organ function. Patients were ineligible if they had symptomatic or untreated central nervous 
system metastases, had received anticancer therapy 14 days or fewer before starting the study, or 
had received previous treatment with a poly(ADP-ribose) polymerase inhibitor. We randomly allocated 
patients 2:1 to receive oral rucaparib 600 mg twice daily or placebo in 28 day cycles using a computer-
generated sequence (block size of six, stratified by homologous recombination repair gene mutation 
status, progression-free interval after the penultimate platinum-based regimen, and best response to 
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the most recent platinum-based regimen). Patients, investigators, site staff, assessors, and the funder 
were masked to assignments. The primary outcome was investigator-assessed progression-free 
survival evaluated with use of an ordered step-down procedure for three nested cohorts: patients with 
BRCA mutations (carcinoma associated with deleterious germline or somatic BRCA mutations), 
patients with homologous recombination deficiencies (BRCA mutant or BRCA wild-type and high loss 
of heterozygosity), and the intention-to-treat population, assessed at screening and every 12 weeks 
thereafter. This trial is registered with ClinicalTrials.gov, number NCT01968213; enrolment is 
complete. 
 
Findings  
Between April 7, 2014, and July 19, 2016, we randomly allocated 564 patients: 375 (66%) to rucaparib 
and 189 (34%) to placebo. Median progression-free survival in patients with a BRCA-mutant 
carcinoma was 16.6 months (95% CI 13.4–22.9; 130 [35%] patients) in the rucaparib group versus 5.4 
months (3.4–6.7; 66 [35%] patients) in the placebo group (hazard ratio 0.23 [95% CI 0.16–0.34]; 
p<0.0001). In patients with a homologous recombination deficient carcinoma (236 [63%] vs. 118 
[62%]), it was 13.6 months (10.9–16.2) versus 5.4 months (5.1–5.6; 0.32 [0.24–0.42]; p<0.0001). In 
the intention-to-treat population, it was 10.8 months (8.3–11.4) versus 5.4 months (5.3–5.5; 0.36 
[0.30–0.45]; p<0.0001). Treatment-emergent adverse events of grade 3 or higher in the safety 
population (372 [99%] patients in the rucaparib group vs. 189 [100%] in the placebo group) were 
reported in 209 (56%) patients in the rucaparib group versus 28 (15%) in the placebo group, the most 
common of which were anaemia or decreased haemoglobin concentration (70 [19%] vs. one [1%]) and 
increased alanine or aspartate aminotransferase concentration (39 [10%] vs. none). 
 
Interpretation  
Across all primary analysis groups, rucaparib significantly improved progression-free survival in 
patients with platinum-sensitive ovarian cancer who had achieved a response to platinum-based 
chemotherapy. ARIEL3 provides further evidence that use of a poly(ADP-ribose) polymerase inhibitor 
in the maintenance treatment setting versus placebo could be considered a new standard of care for 
women with platinum-sensitive ovarian cancer following a complete or partial response to second-line 
or later platinum-based chemotherapy. 
